| Schedule of Breakdown of Research and Development Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
For the six months ended June 30, |
|
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
|
|
€ |
|
€ |
|
€ |
|
€ |
|
Clinical |
|
|
(20,769,302 |
) |
|
(14,712,960 |
) |
|
(35,401,888 |
) |
|
(32,049,342 |
) |
Personnel (Note 5) |
|
|
(10,761,205 |
) |
|
(9,351,648 |
) |
|
(20,750,961 |
) |
|
(17,777,098 |
) |
Nonclinical |
|
|
(1,053,570 |
) |
|
(2,858,075 |
) |
|
(2,221,861 |
) |
|
(4,708,265 |
) |
Manufacturing |
|
|
(1,342,173 |
) |
|
(2,571,095 |
) |
|
(5,445,858 |
) |
|
(5,799,627 |
) |
License fees |
|
|
(1,000,000 |
) |
|
— |
|
|
(1,000,000 |
) |
|
— |
|
Intellectual Property |
|
|
(73,918 |
) |
|
(114,130 |
) |
|
(340,762 |
) |
|
(187,969 |
) |
|
|
|
(35,000,168 |
) |
|
(29,607,908 |
) |
|
(65,161,330 |
) |
|
(60,522,301 |
) |
|